N/A
Completed N=18
PharmacoMRI of Parkinson Disease
Source: ClinicalTrials.gov NCT01528592 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Dec 2013
Primary outcomePrimary: Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex. — 0.5869 unitless
Summary
Based on studies showing better responsiveness of motor versus cognitive symptoms to Parkinson's Disease medication, also known as dopaminergic treatments, the investigators hypothesize that comparison of resting state networks in the on versus off medication state in Parkinson's Disease patients will show greater effects on brain networks associated with motor control.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex. |
0.5869 | — |
Eligibility Criteria
Inclusion Criteria
- Idiopathic Parkinson's Disease (PD)
- Older than 30 years of age at the time of diagnosis
- Hoehn and Yahr stage greater than or equal to 2.5
- PD duration greater than 3 years
- Stable regimen of PD medications for at least 2 weeks prior to imaging
- PD medications include carbidopa-levodopa
Exclusion Criteria
- Patients with a diagnosis of other neurodegenerative conditions
- Patients unwilling or unable to give informed consent
- Contraindications (cardiac pacemaker, etc.) or inability (e.g., claustrophobia) to undergo MRI scan
Data sourced from ClinicalTrials.gov (NCT01528592). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.